Kolexia
Cassier Philippe Oncologie médicale
Cassier Philippe
Oncologie médicale
Centre Léon-Bérard
Lyon, France
416 Activités
176 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Carcinomes Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Tumeurs stromales gastro-intestinales Cholangiocarcinome Tumeurs colorectales Métastase tumorale

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Perol David
Perol David
Centre Léon-Bérard, Lyon, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Amgen
8 collaboration(s)
Dernière en 2021
MSD
1 collaboration(s)
Dernière en 2022
Novartis
1 collaboration(s)
Dernière en 2023
Pierre Fabre
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors: A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Essai Clinique (Kinnate Biopharma)   11 mars 2024
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Essai Clinique (Loxo Oncology, Inc.)   01 mars 2024
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors: A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
Essai Clinique (C4 Therapeutics, Inc.)   29 février 2024
Patients' selection and trial matching in early-phase oncology clinical trials.
Critical reviews in oncology/hematology   23 février 2024
ARROW: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Essai Clinique (Roche)   21 février 2024
A Study of TAS-120 in Patients With Advanced Solid Tumors: Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Essai Clinique (Taiho Oncology, Inc.)   20 février 2024
FLUORIB: Analysis of the Impact of 5-Fluorouracil on the Translational Control and Plasticity of Cancer Cells From Liver Metastases of Colon Cancer
Essai Clinique (Centre Léon-Bérard)   12 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158): A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Essai Clinique (Merck & Co.)   02 février 2024